Format

Send to

Choose Destination
J Thorac Oncol. 2018 Jul;13(7):996-1003. doi: 10.1016/j.jtho.2018.03.020. Epub 2018 Mar 30.

Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711).

Author information

1
State University of New York Upstate, Syracuse, New York.
2
Mayo Clinic, Rochester, Minnesota.
3
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
4
University of California San Francisco Medical Center, San Francisco, California.
5
Roswell Park Cancer Institute, Buffalo, New York.
6
University of Rochester Medical Center, Rochester, New York.
7
City of Hope Comprehensive Cancer Center, Duarte, California.
8
University of North Carolina - Chapel Hill, Chapel Hill, North Carolina.
9
Center for the Study of Aging and Human Development and Cancer Institute, Duke University, Durham, North Carolina, Duke Cancer Institute, Duke University, Durham, North Carolina.
10
Fox Chase Cancer Center, Philadelphia, Pennsylvania.
11
Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
12
Mayo Clinic, Rochester, Minnesota. Electronic address: Le-Rademacher.jennifer@mayo.edu.

Abstract

INTRODUCTION:

Time-to-treatment-failure (TTF) is the interval from chemotherapy initiation to premature discontinuation. We evaluated TTF based on age.

METHODS:

Pooled analyses were conducted with first-line chemotherapy trials for advanced NSCLC (CALGB 9730, 30203, and 30801). Comparisons among patients who were 65 years and older and 70 years and older were performed for TTF (primary endpoint), reasons for early chemotherapy cessation, grade 3+ adverse events, and overall survival.

RESULTS:

Among 1006 patients, 460 (46%) were older than 65 years of age. One hundred forty-five older patients (32% of this age cohort) completed all six planned chemotherapy cycles as did 170 (32%) younger patients. Median TTF was 2.9 months (95% confidence interval: 2.7- 3.2) in older patients and 3 months (95% confidence interval: 2.9-3.5) in younger patients; adjustment for performance status and stratification by chemotherapy by trial yielded no statistically significant age-based difference in TTF. However, reasons for early chemotherapy cessation differed between age groups (multivariate p = 0.004). Older patients were less likely to discontinue from cancer progression (41% versus 55%) and more likely from toxicity or patient choice (16% and 15%, respectively) compared to younger patients (13% and 6%, respectively). Older patients were more likely to experience grade 3+ adverse events (86% versus 79%) with no statistically significant difference in survival. An age cutpoint of 70+ years showed no difference in TTF, a lower trend of early cessation due to cancer progression, and somewhat shorter older patient survival.

CONCLUSIONS:

TTF was comparable between older and younger patients; but different, age-based, and potentially modifiable reasons account for it.

KEYWORDS:

Adverse events; Chemotherapy cessation; Geriatric; Non–small cell lung cancer; Time-to-treatment failure

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center